Spero Therapeutics Inc. (SPRO)

NASDAQ: SPRO · Real-Time Price · USD

0.65

-0.01 (-1.52%)

At close: May 02, 2025, 10:24 AM

Spero Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Net Income	-68.57M	22.81M	-46.41M	-89.76M	-78.28M	-60.92M	-41.66M	-39.89M	-32.64M
Depreciation & Amortization	2K	367K	869K	646K	761K	750K	409K	363K	279K
Stock-Based Compensation	7.79M	7.93M	9.12M	9.43M	4.89M	3.78M	2.75M	1.43M	180K
Other Working Capital	30.36M	-71.14M	22.57M	12.95M	-10.42M	6.27M	-1.16M	-1.91M	-148K
Other Non-Cash Items	1.04M	6.28M	6.61M	2.37M	513K	356K	-50K	-1.54M	4.59M
Deferred Income Tax	n/a	n/a	n/a	60K	-362K	-808K	n/a	83K	-580K
Change in Working Capital	36.28M	-70.38M	22.09M	12.9M	-13.39M	6.83M	-1.07M	443K	-792K
Operating Cash Flow	-23.44M	-32.99M	-7.73M	-64.35M	-85.87M	-50.02M	-39.63M	-39.11M	-28.96M
Capital Expenditures	n/a	n/a	n/a	39K	-157K	-314K	-2.44M	-27K	-830K
Cash Acquisitions	n/a	n/a	n/a	-39K	-10.63M	-29.84M	83.16M	-1.18M	n/a
Purchase of Investments	n/a	n/a	-26.97M	-43.91M	-45.72M	-88.99M	-130.18M	n/a	n/a
Sales Maturities Of Investments	n/a	n/a	60.78M	51.55M	56.35M	118.84M	49.45M	n/a	n/a
Other Investing Acitivies	n/a	n/a	33.81M	39K	10.63M	29.84M	-83.16M	-27K	n/a
Investing Cash Flow	n/a	n/a	33.81M	7.67M	10.47M	29.53M	-83.16M	-27K	-830K
Debt Repayment	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	n/a	n/a	-54.06M	48.68M	1.24M	350K	-977K	-4.75M	8.5M
Financial Cash Flow	n/a	221K	-29.55M	84.05M	130.88M	16.14M	69.52M	116.11M	34.41M
Net Cash Flow	-23.44M	-32.77M	-3.48M	27.38M	55.48M	-4.35M	-53.26M	76.97M	4.62M
Free Cash Flow	-23.44M	-32.99M	-7.73M	-64.31M	-86.03M	-50.33M	-42.06M	-39.14M	-29.79M